Ellipses Pharma is a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset.

Ellipses Pharma

Ellipses Pharma | 3,072 followers on LinkedIn. Ellipses Pharma is focused exclusively on the development of innovative cancer medicines and treatments.  | Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference.

Liz Clark

Head of Digital, Data and Technology at Ellipses Pharma

Luke Slatford

Head of CMC, Ellipses Pharma

Graeme Horne

Chief Financial Officer at Ellipses Pharma

David Cook

Please join us in celebrating Dr Sital Patel who has been with us for 5 years this month. Joining the team back in 2019, Sital worked with the late Professor Gordon Mc Vie. She was instrumental in applying her talent and experience in developing strong relationships with healthcare professionals to help grow our Scientific Affairs Group (SAG). We are proud that our SAG has grown to 300+ international oncology KOLs. Sital brings deep scientific acumen to her latest role within Translational Medicine, underpinned by her strong academic and research background. Her expertise enables us to bridge the gap from early-stage research and clinical application, ensuring we look at the most relevant and scientifically robust assets. Congratulations and thank you, Sital, for everything you have achieved and contributed to Ellipses Pharma.

Our Head of Finance, Eden Demmisse , and Head of Digital, Data, and Technology, Luke Slatford , are both attending Gartner’s IT Symposium/Xpo in Barcelona next week. Eden is excited for her first Symposium and will be attending sessions on Strategy, Leadership, and Sustainability—say hi if you see her! Luke will be onstage at the Monday morning orientation and participating in the Alumni Panel interview on Tuesday afternoon. If you’re at the event, be sure to introduce yourself to them, they'd love to connect!

In October, we recognise Breast Cancer Awareness Month. Every year, over 55,000 people are diagnosed with breast cancer in the UK alone*. Today and every day, we stand with all those affected by breast cancer. At Ellipses Pharma , we are committed to accelerating drug development to improve cancer treatment options for patients. We remain focused on getting the best therapeutics to the right patients at the right time. #BreastCancer #BreastCancerAwarenessMonth #DrugDevelopment *Source: Breast Cancer Now https://lnkd.in/eVXbqu4g

More opportunities: More Trials: More Lives Saved.

In the UK, around 55,000 women and 400 men are diagnosed with breast cancer annually. That’s 1 in 7 women. The survival rate continues to improve and has doubled in the past 50 years, achieved thanks to better diagnosis and detection, screenings, and of course, improved therapeutics.* And yet it is the 4th most common cause of cancer related deaths in the UK. We have adopted a unique approach that accelerates the drug development process, and focuses on getting the best therapeutics to patients rapidly, in a safe and effective way. Speed doesn’t mean cutting corners: it’s about minimising delays, reducing risk involved in selecting potential new drugs, and most importantly, enhancing treatment success rates. You may have seen UICC’s Rewriting Cancer series, produced for them by BBC StoryWorks Commercial Productions. Professor Tobias Arkenau features in part one - Changing the Odds, where he discusses how we’re disrupting the clinical trials’ process to accelerate the availability of promising new therapeutics with the aim of improving survival rates, as well as quality of life for those going through cancer treatment. In oncology we all share a common goal to improve the lives of patients. Now available to stream in the UK here: https://lnkd.in/eUsRSAyi , and outside of the UK here: https://lnkd.in/e89fpS3A #RewritingCancer #Cancer #BreastCancerAwarenessMonth #ClinicalTrials #DrugDevelopment #OncologyDrugDevelopment *Reference: Breast Cancer Now statistics for 2024 https://lnkd.in/gZcikCCM

Our Scientific Affairs Group (SAG) is a world-class, highly experienced team of over 300 oncology experts with global reach who we work with to help validate the science and clinical application of our assets. This approach provides us with an oncology-focused consensus that ensures in-licensed assets are appropriately developed. Learn more about the largest global panel of key opinion leaders in oncology https://lnkd.in/ezDnfYjb

Rewriting Cancer is an informative series presented by UICC and produced for them by BBC StoryWorks and we are proud to be involved in this unique project. In the episode featuring Ellipses Pharma our CMO and Global Head of Drug Development Professor Tobias Arkenau explains our innovative approach to clinical trials and we hear from patient Nina Lopes, who is living with terminal breast cancer, talk about her cancer journey. Patients deserve a better clinical trial landscape, where a greater volume of trials are offered much earlier and not as a last resort. Nina explains her experience in participating in clinical trials and how they have enabled her to carry on living her life to the full. So what makes our approach different? Tobi outlines how Ellipses Pharma aims to minimise delays in the drug development process, reduce the risk involved in selecting potential new drugs and, most importantly, enhance treatment success rates for patients around the world. Crucially, we have assembled the largest Scientific Affairs Group, made up of over 300 renowned oncology experts from around the globe to provide insights on our clinical trials from inception to finish. They evaluate the next generation of potential assets and provide critical insights into trial design. To hear more about Nina’s story and understand Ellipses Pharma’s approach to oncology drug development, please watch the full video on our site https://ellipses.life/ #Cancer #OncologyInnovation , #CancerResearch #EllipsesPharma , #PrecisionMedicine , #ClinicalTrials #biotech #DrugDevelopment #OncologyDrugDevelopment

We are delighted to announce our involvement in Rewriting Cancer, a series produced for UICC by BBC StoryWorks Commercial Productions. This unique project examines the complexity of cancer and the changes in treatments that are required to achieve better outcomes for patients. Watch and learn how we and the other participants are Rewriting Cancer. In oncology we all share a common goal to improve the lives of patients. You can watch the series here if you're in the UK: https://lnkd.in/eUsRSAyi or, click here if you're outside the UK: https://lnkd.in/e89fpS3A #RewritingCancer #Cancer #OncologyInnovation , #CancerResearch #EllipsesPharma , #PrecisionMedicine , #ClinicalTrials #biotech #DrugDevelopment #OncologyDrugDevelopment

As ESMO - European Society for Medical Oncology comes to a close, we are reflecting on all of the exciting developments we shared with everyone for EP0031 (A400/KL590586), a promising next generation selective RET inhibitor (SRI). Some key takeaways Elena Garralda Cabanas shared from our poster and presentation this weekend: - The poster presented at ESMO 2024 shows that EP0031 has an encouraging safety profile with evidence of efficacy in patients naïve to, or previously treated with 1st generation SRIs, and activity against brain metastases. - The in depth biomarker analysis presented supports the efficacy of EP0031 in patients that previously received a 1st gen SRI – independent of the presence of emergent RET resistance mutations. - Reductions in methylation-based tumour fractions and ctDNA appear to correlate with response to EP0031, with reductions in on-target RET resistance mutations also observed when present. The data highlights the early promise of these ctDNA-based methodologies as predictive biomarkers. - The Ellipses Phase 2 study continues to enrol patients in the US, UK and EU. Read the poster in full: https://lnkd.in/ew8UmfBs #OncologyDrugDevelopment #EllipsesPharma #EP0031 #ESMO2024 #ClinicalTrials

As we approach ESMO - European Society for Medical Oncology Congress 2024 (13 - 17 September 2024, Barcelona, Spain), we want to extend our sincere gratitude to our Scientific Affairs Group (SAG). Your invaluable contributions are shaping the future of oncology therapeutics, and we are honoured to have over 300 world-class oncology experts from around the globe as part of our team. Your real-world insights on our clinical trial planning are crucial to our success, and for that, we thank you. If you're attending ESMO, we’d love the opportunity to connect in person. Please reach out to Professor Tobias Arkenau or Shabaaz Ali to arrange a meeting. We look forward to seeing you there!

Metric
Company Name	Ellipses Pharma
Symbol
MSH ID	LIFE:ELLIPSES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	GB
Stage
Employee Count
Website	ellipses.life
LinkedIn	ellipses-pharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ELLI

LIFE:ELLIPSES

Ellipses Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue